Last reviewed · How we verify
Initial Heparin Dose Modification
At a glance
| Generic name | Initial Heparin Dose Modification |
|---|---|
| Also known as | Use of a patient specific calculator to determine therapeutic dose at initiation of heparin |
| Sponsor | Inova Health Care Services |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (PHASE4)
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
- STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis (PHASE4)
- Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital (PHASE4)
- TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PHASE3)
- Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial (PHASE2, PHASE3)
- DOAC Versus VKA After Cardiac Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Initial Heparin Dose Modification CI brief — competitive landscape report
- Initial Heparin Dose Modification updates RSS · CI watch RSS
- Inova Health Care Services portfolio CI